866-997-4948(US-Canada Toll Free)

Investigation Report on China Raloxifene Market, 2010-2019

Published By :

China Research and Intelligence Co., Ltd. (CRI)

Published Date : Jun 2015

Category :

Manufacturing, Packaging & Detailing

No. of Pages : 30 Pages

According to the statistics, over 200 million people suffer from osteoporosis in the world. Among women aged 50 and above in China, 50% have low bone mass or osteoporosis while this figure is 30%-50% among women aged 60 and above.

Raloxifene (raloxifene hydrochloride), a non-hormone drug against bone resorption, belongs to the second generation of selective estrogen receptor modulator (SERMs). Different from traditional estrogen replacement therapy (ERT) or hormone replacement therapy (HRT), raloxifene can not only prevent postmenopausal women from osteoporosis but also effectively increase bone mass and bone density so as to treat postmenopausal osteoporosis and prevent osteoporotic fracture.

When raloxifene made by Eli Lilly under the trade name of Evista entered the market in 1997, its global sales value in the first year reached up to 285 million, making it the second most successful product of Eli Lilly. However, raloxifene’s annual sales value has been fluctuating around USD 1 billion after it reached its sales peak of USD 1.091 billion in 2007.

Raloxifene made by local enterprises came into the market after Evista entered China in Oct. 2003 and raloxifene’s CAGR was about 14% during the period of 2005-2014 according to CRI’s survey. Raloxifene enjoys a vast demand in China. Currently, raloxifene in the Chinese market are monopolized by the following three companies: Eli Lilly and Company (Spain), Eli Lilly and Company (UK) and Jiangsu Hengrui Medicine Co., Ltd, among which Eli Lilly and Company (Spain) has the largest market share of 86% for sales value in 2014.

Raloxifene market in China is expected to grow in the next few years.

Readers can get at least the following information from this report:
  • market size of raloxifene in China
  • competitive landscape of raloxifene in Chinese market
  • price of raloxifene made by different enterprises in China
  • market outlook of raloxifene in China
The author suggests the following groups of people purchase this report:
  • drug manufacturers
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service
Table of Content

1 Related Concepts of Raloxifene
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Raloxifene in China
2.1 Patent and Approval Status of Raloxifene in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Raloxifene in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Manufacturers of Raloxifene in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Raloxifene in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Raloxifene in Chinese Hospitals in 2014
6.1 Jiangsu Hengrui Medicine Co., Ltd (Trade Name: Bei Bang)
6.2 Eli Lilly and Company (UK) (Trade Name: Evista)
6.3 Eli Lilly and Company (Spain) (Trade Name: Evista)

7 Major Manufacturers of Raloxifene in Chinese Market, 2010-2014
7.1 Jiangsu Hengrui Medicine Co., Ltd
7.2 Eli Lilly and Company

8 Market Outlook of Raloxifene in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

List of Chart


Chart Approval Information of Raloxifene in China
Chart Sales Status of Raloxifene in China
Chart Sales Value of Raloxifene in China, 2010-2014
Chart Sales Value of Raloxifene in Some Regions in China, 2010-2014
Chart Sales Volume of Raloxifene in China, 2010-2014
Chart Market Share of TOP3 Manufacturers of Raloxifene for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Raloxifene Made by Eli Lilly (Spain) in China, 2010-2014
Chart Sales Value and Market Share of Raloxifene Made by Jiangsu Hengrui in China, 2010-2014
Chart Sales Value and Market Share of Raloxifene Made by Eli Lilly (UK) in China, 2010-2014
Chart Sales Value and Market Share of Raloxifene Made by Other Manufacturers in China, 2010-2014
Chart Price of Raloxifene Made by Jiangsu Hengrui Medicine Co., Ltd in Some Chinese Cities in 2014
Chart Price of Raloxifene Made by Eli Lilly and Company (UK) in Some Chinese Cities in 2014
Chart Price of Raloxifene Made by Eli Lilly and Company (Spain) in Some Chinese Cities in 2014

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *